Bronchopulmonary Dysplasia Clinical Presentation

1. Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2012 Jan. 97(1):F8-F17. [QxMD MEDLINE Link].

2. Viscardi RM, Muhumuza CK, Rodriguez A, et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res. 2004 Jun. 55(6):1009-17. [QxMD MEDLINE Link]. [Full Text].

3. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967 Feb 16. 276(7):357-68. [QxMD MEDLINE Link].

4. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979 Nov. 95(5 Pt 2):819-23. [QxMD MEDLINE Link].

5. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct. 82(4):527-32. [QxMD MEDLINE Link].

6. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun. 163(7):1723-9. [QxMD MEDLINE Link].

7. Walsh MC, Yao Q, Gettner P, et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics. Nov 2004. 114:1305-11. [QxMD MEDLINE Link].

8. Laughon MM, Langer JC, Bose CL, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med. 2011 Jun 15. 183(12):1715-22. [QxMD MEDLINE Link]. [Full Text].

9. Ambalavanan N, Carlo WA. Bronchopulmonary dysplasia: new insights. Clin Perinatol. Sept 2004. 31:613-28. [QxMD MEDLINE Link].

10. Torchin H, Lorthe E, Goffinet F, et al. Histologic chorioamnionitis and bronchopulmonary dysplasia in preterm infants: the epidemiologic study on low gestational ages 2 cohort. J Pediatr. 2017 Aug. 187:98-104.e3. [QxMD MEDLINE Link].

11. Ballard AR, Mallett LH, Pruszynski JE, Cantey JB. Chorioamnionitis and subsequent bronchopulmonary dysplasia in very-low-birth weight infants: a 25-year cohort. J Perinatol. 2016 Dec. 36(12):1045-8. [QxMD MEDLINE Link].

12. Lal CV, Travers C, Aghai ZH, et al. The airway microbiome at birth. Sci Rep. 2016 Aug 4. 6:31023. [QxMD MEDLINE Link]. [Full Text].

13. Kresch MJ, Clive JM. Meta-analyses of surfactant replacement therapy of infants with birth weights less than 2000 grams. J Perinatol. 1998 Jul-Aug. 18(4):276-83. [QxMD MEDLINE Link].

14. Van Marter LJ, Allred EN, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics. 2000 Jun. 105(6):1194-201. [QxMD MEDLINE Link].

15. Hakulinen AL, Heinonen K, Lansimies E, Kiekara O. Pulmonary function and respiratory morbidity in school-age children born prematurely and ventilated for neonatal respiratory insufficiency. Pediatr Pulmonol. 1990. 8(4):226-32. [QxMD MEDLINE Link].

16. Northway WH Jr. Bronchopulmonary dysplasia: twenty-five years later. Pediatrics. 1992 May. 89(5 Pt 1):969-73. [QxMD MEDLINE Link].

17. Bader D, Ramos AD, Lew CD, et al. Childhood sequelae of infant lung disease: exercise and pulmonary function abnormalities after bronchopulmonary dysplasia. J Pediatr. 1987 May. 110(5):693-9. [QxMD MEDLINE Link].

18. Blayney M, Kerem E, Whyte H, O'Brodovich H. Bronchopulmonary dysplasia: improvement in lung function between 7 and 10 years of age. J Pediatr. 1991 Feb. 118(2):201-6. [QxMD MEDLINE Link].

19. Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics. Mar 2012. 129(3):e682-9. [QxMD MEDLINE Link]. [Full Text].

20. Carlton EF, Sontag MK, Younoszai A, et al. Reliability of echocardiographic indicators of pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. J Pediatr. 2017 Jul. 186:29-33. [QxMD MEDLINE Link]. [Full Text].

21. Krishnan U, Feinstein JA, Adatia I, et al, for the Pediatric Pulmonary Hypertension Network (PPHNet). Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr. 2017 Sep. 188:24-34.e1. [QxMD MEDLINE Link]. [Full Text].

22. Jobe AJ. The new BPD: an arrest of lung development. Pediatr Res. 1999 Dec. 46(6):641-3. [QxMD MEDLINE Link].

23. Kim BI, Lee HE, Choi CW, et al. Increase in cord blood soluble E-selectin and tracheal aspirate neutrophils at birth and the development of new bronchopulmonary dysplasia. J Perinat Med. 32(3):282-7. [QxMD MEDLINE Link].

24. Borghesi A, Massa M, Campanelli R, et al. Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2009 Sep 15. 180(6):540-6. [QxMD MEDLINE Link].

25. Carlo WA, Finer NN, Walsh MC, et al, for the SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Target ranges of oxygen saturation in extremelypreterm infants. N Engl J Med. May 2010. 362(21):1959-69. [QxMD MEDLINE Link]. [Full Text].

26. Oh W, Poindexter BB, Perritt R, et al, for the Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005 Dec. 147(6):786-90. [QxMD MEDLINE Link].

27. Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics. 2006 Mar. 117(3 Pt 2):S52-6. [QxMD MEDLINE Link].

28. Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. J Perinatol. 2000 Jan-Feb. 20(1):41-5. [QxMD MEDLINE Link].

29. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006 May 18. 354(20):2112-21. [QxMD MEDLINE Link].

30. Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998 Apr 16. 338(16):1112-8. [QxMD MEDLINE Link].

31. [Guideline] AAP. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics. 1998 Nov. 102(5):1211-6. [QxMD MEDLINE Link].

32. [Guideline] American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003 Dec. 112(6 Pt 1):1442-6. [QxMD MEDLINE Link]. [Full Text].

33. Bassler D, Plavka R, Shinwell ES, et al, for the NEUROSIS Trial Group. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med. 2015 Oct 15. 373(16):1497-506. [QxMD MEDLINE Link]. [Full Text].

34. Ambalavanan N, Tyson JE, Kennedy KA, et al. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005 Mar. 115(3):e249-54. [QxMD MEDLINE Link].

35. Bourbia A, Cruz MA, Rozycki HJ. NF-kappaB in tracheal lavage fluid from intubated premature infants: association with inflammation, oxygen, and outcome. Arch Dis Child Fetal Neonatal Ed. 2006 Jan. 91(1):F36-9. [QxMD MEDLINE Link].

36. Brundage KL, Mohsini KG, Froese AB, Fisher JT. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1990 Nov. 142(5):1137-42. [QxMD MEDLINE Link].

37. Douglas D. Hydrocortisone seems safe in infantile bronchopulmonary dysplasia. June 05, 2013. Medscape Medical News. Available at http://www.medscape.com/viewarticle/805393. Accessed: June 10, 2013.

38. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005 Dec. 116(6):1353-60. [QxMD MEDLINE Link].

39. Jobe AH. Antenatal associations with lung maturation and infection. J Perinatol. 2005 May. 25 Suppl 2:S31-5. [QxMD MEDLINE Link].

40. Kakkera DK, Siddiq MM, Parton LA. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biol Neonate. 2005. 87(2):82-90. [QxMD MEDLINE Link].

41. Kallapur SG, Jobe AH. Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed. 2006 Mar. 91(2):F132-5. [QxMD MEDLINE Link].

42. Kersbergen KJ, de Vries LS, van Kooij BJ, et al. Hydrocortisone treatment for bronchopulmonary dysplasia and brain volumes in preterm infants. J Pediatr. 2013 Sep. 163(3):666-71.e1. [QxMD MEDLINE Link]. [Full Text].

43. Korhonen P, Hyodynmaa E, Lautamatti V, et al. Cardiovascular findings in very low birthweight schoolchildren with and without bronchopulmonary dysplasia. Early Hum Dev. 2005 Jun. 81(6):497-505. [QxMD MEDLINE Link].

44. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 2005 Dec. 24(12):1033-9. [QxMD MEDLINE Link].

45. Smith VC, Zupancic JA, McCormick MC. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr. 2005 Apr. 146(4):469-73. [QxMD MEDLINE Link].

46. Stoelhorst GM, Rijken M, Martens SE, et al, for the Leiden Follow-Up Project on Prematurity. Changes in neonatology: comparison of two cohorts of very preterm infants (gestational age Pediatrics</i>. 2005 Feb. 115(2):396-405. [QxMD MEDLINE Link].

47. Kunjunju AM, Gopagondanahalli KR, Chan Y, Sehgal A. Bronchopulmonary dysplasia-associated pulmonary hypertension: clues from placental pathology. J Perinatol. 2017 Dec. 37(12):1310-4. [QxMD MEDLINE Link].

48. Choi CW. Chorioamnionitis: Is a major player in the development of bronchopulmonary dysplasia?. Korean J Pediatr. 2017 Jul. 60(7):203-7. [QxMD MEDLINE Link]. [Full Text].

49. Johnson AK, Lynch N, Newberry D, Jnah AJ. Impact of diuretic therapy in the treatment of bronchopulmonary dysplasia and acute kidney injury in the neonatal population. Adv Neonatal Care. 2017 Oct. 17(5):337-46. [QxMD MEDLINE Link].

50. Perez Tarazona S, Solano Galan P, Bartoll Alguacil E, Alfonso Diego J. Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: a systematic review. Allergol Immunopathol (Madr). 2018 Jan - Feb. 46(1):87-98. [QxMD MEDLINE Link].

51. Bashir RA, Bhandari V, Vayalthrikkovil S, et al. Chorioamnionitis at birth does not increase the risk of neurodevelopmental disability in premature infants with bronchopulmonary dysplasia. Acta Paediatr. 2016 Nov. 105(11):e506-e512. [QxMD MEDLINE Link].

52. Torchin H, Ancel PY, Goffinet F, et al. Placental complications and bronchopulmonary dysplasia: EPIPAGE-2 Cohort Study. Pediatrics. 2016 Mar. 137(3):e20152163. [QxMD MEDLINE Link]. [Full Text].

53. Clouse BJ, Jadcherla SR, Slaughter JL. Systematic review of inhaled bronchodilator and corticosteroid therapies in infants with bronchopulmonary dysplasia: implications and future directions. PLoS One. 2016. 11(2):e0148188. [QxMD MEDLINE Link]. [Full Text].

54. Yang J, Kingsford RA, Horwood J, et al. Lung function of adults born at very low birth weight. Pediatrics. 2020 Jan 3. [QxMD MEDLINE Link].

55. Varghese N, Rios D. Pulmonary hypertension associated with bronchopulmonary dysplasia: a review. Pediatr Allergy Immunol Pulmonol. 2019 Dec 1. 32(4):140-8. [QxMD MEDLINE Link]. [Full Text].

Namasivayam Ambalavanan, MD, MBBS Professor, Director of Neonatal Research, Director of Fellowship Program, Division of Neonatology, Departments of Pediatrics, Cell Biology, and Pathology, University of Alabama School of Medicine

Namasivayam Ambalavanan, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Physiological Society, American Thoracic Society, Medical Association of the State of Alabama, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Shire LLC; Radiometer; ResBiotic<br/>Received research grant from: NIH.

Arun K Pramanik, MD, MBBS Professor of Pediatrics, Louisiana State University Health Sciences Center

Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National Perinatal Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Muhammad Aslam, MD Professor of Pediatrics, University of California, Irvine, School of Medicine; Neonatologist, Division of Newborn Medicine, Department of Pediatrics, UC Irvine Medical Center

Muhammad Aslam, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous authors William Driscoll, DO, and Jonathan Davis, MD, as well as previous coauthor Thomas D Soltau, MD, to the development and writing of this article.

• Print this section
• Print the entire contents of
• Print the entire contents of article